Zydus Lifesciences Limited

BSE: 532321 NSE: ZYDUSLIFE
Zydus Lifesciences Limited - pharma in Ahmedabad, Gujarat, India. FY 2026 financials & compliance.
CIN L24230GJ1995PLC025878 Incorporated 15 May 1995 ROC Ahmedabad HQ Ahmedabad, Gujarat, India
Active Listed - NSE: ZYDUSLIFE · BSE: 532321 Public Limited Company pharma Fortune India 500 · #117 Nifty 500
Data last updated
Market Cap
₹1,18,144 Cr
ZYDUSLIFE · NSE
Share Price
₹1,245.50
+5.16% today
Revenue
₹51,180 Cr
FY 2025-26 · +13.2% YoY
EBITDA
₹7,958 Cr
Margin 15.6%
Net Profit
₹5,432 Cr
FY 2025-26 · +16.8% YoY
P/E (TTM)
24.0x
P/B 4.3x
ROE
19.7%
ROCE 20.3%
Debt / Equity
0.31
Interest cover 6.7x

About Zydus Lifesciences Limited

Data last updated:

Zydus Lifesciences Limited is a public limited company based in Ahmedabad, Gujarat, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 15 May 1995 and has been in existence for over 31 years.

Zydus Lifesciences is ranked #117 on the Fortune India 500 (2025). It is part of the Nifty 500 and BSE 500 indices. Its director Pankaj Patel and family are #27 among India's richest people (2026). Its director Bhadresh Shah is #132 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L24230GJ1995PLC025878. Its GSTIN is 24AAACC6253G1ZZ (Gujarat). The company holds 38 GST registrations, of which 27 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 532321 and NSE: ZYDUSLIFE.

The company has an authorised share capital of ₹172.5 Cr and a paid-up capital of ₹99.75 Cr. It was formerly known as Cadila Healthcare Private Limited. It is led by directors including Sharvil Pankajbhai Patel (Managing Director) and Bhadresh Kantilal Shah.

Its last annual general meeting (AGM) was held on 11 August 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Zydus Corporate Park, Ahmedabad, Gujarat.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹51,180 Cr, a growth of 13.2% compared to the previous year. For the same year it recorded a net profit of ₹5,432.39 Cr (net margin 10.6%) and EBITDA of ₹7,958.5 Cr (EBITDA margin 15.5%). The net worth stands at ₹27,111 Cr (up 13.2% YoY). Total assets are valued at ₹43,600 Cr (up 41.4% YoY).

The company has about 13,762 employees on its provident fund (EPFO) records. Its group structure includes 16 subsidiaries and 3 joint ventures.

The company is associated with 3 brands: Zydus, Zydus Cadila and Zydus Life. As per MCA filings, the company has open charges of ₹1,500 Cr and satisfied charges of ₹3,001.83 Cr on record. Court records list 167 cases involving the company, including 128 filed by the company and 39 filed against it; 63 cases are pending. The company has 17 deals on record (10 market trades, 5 secondary share transfers, 1 buyback); the latest was in August 2024. Its 9 peer companies in the Pharma industry (Formulations, Lifesciences), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 5 smaller; the largest is Sun Pharmaceutical Industries Limited with revenue of ₹54,543 Cr. The company has 10 MSME Form 1 returns on record between 2019 and 2024, listing 722 overdue payments to 180 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website zyduslife.com.

Company details

CIN L24230GJ1995PLC025878
Registration Number 025878
Incorporation Date 15 May 1995
ROC Ahmedabad
Listing Status Listed - Listed on NSE (ZYDUSLIFE); Listed on BSE (532321)
Company Status Active
Date of Last AGM 11 August 2026
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

CIN history

Zydus Lifesciences has one previous CIN (Corporate Identification Number): U24230GJ1995PLC025878. The current CIN is L24230GJ1995PLC025878, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24230GJ1995PLC025878Current
U24230GJ1995PLC025878Previous
Key People
Sharvil Pankajbhai Patel Managing Director Bhadresh Kantilal Shah Director Monappa Arun Akhil Director

Recognitions & Rankings of Zydus Lifesciences

Fortune India 500 2025 edition
Rank#117
Total income
₹23,696 Cr
Profit
₹4,526 Cr
Last year #122
India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#66
Valuation
₹98,910 Cr
2023 #78 2022 #92 2021 #83
Stock market indices
Nifty 500 BSE 500

Contact details

Zydus Lifesciences Limited's registered office is in Ahmedabad, Gujarat. Its website is zyduslife.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    zyduslife.com
  • Social Media
  • Registered Address
    Zydus Corporate Park Scheme No. 63 Survey No. 536 Khoraj(Gandhinagar) Nr. Vaishnodevi Circ, Le, Ahmedabad, Gujarat, India – 382481
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Zydus Lifesciences Limited, buy the company report.

Comprehensive company report
Zydus Lifesciences Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Zydus Lifesciences operates multiple associated brands including Zydus, Zydus Cadila, and Zydus Life. Each brand links to its own profile.

BrandDescriptionWebsite
Zydus Cadila
Pharmaceutical manufacturing, drug development, and healthcare services.zyduscadila.com
Zydus Life
Manufacturer of pharmaceutical products, including formulations, APIs, vaccines, and biosimilarszyduslife.com
Zydus
Pharmaceutical products are manufactured and researched by Zydus globally.zydus.ru

Business activity

The main business activity of Zydus Lifesciences is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Zydus Lifesciences Limited, buy the company report.

Financials of Zydus Lifesciences Limited

FY 2025-26 filings available

Zydus Lifesciences Limited reported revenue of ₹51,180 Cr (up 13.2% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹51,180 Cr
+13.2% YoY
EBITDA
₹7,958 Cr
+16.4% YoY
Profit After Tax
₹5,432 Cr
+16.8% YoY
Net Worth
₹27,111 Cr
+13.2% YoY
Total Assets
₹43,600 Cr
+41.4% YoY
Total Debt
₹12,496 Cr
+288.9% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue51,18045,20219,54717,23715,26515,10214,253
Revenue growth+13.2%+131.2%+13.4%+12.9%+1.1%+6.0%-
EBITDA7,9586,8395,3673,2513,3413,1362,420
EBITDA margin+15.6%+15.1%+27.5%+18.9%+21.9%+20.8%+17.0%
Profit before tax6,6216,0274,8322,5855,0842,2851,495
Net profit5,4324,6503,8602,3884,3652,3001,437
Net profit margin+10.6%+10.3%+19.8%+13.9%+28.6%+15.2%+10.1%
EPS (₹)50.1044.9938.3619.3743.8220.8411.49
Balance sheet
Total assets43,60030,82924,27421,21023,65819,87819,979
Net worth27,11123,95319,83017,51617,00012,99210,376
Total debt12,4963,2138041,1954,2214,5847,986
Cash & bank1,4172,9571,1055731,107888965
Net working capital7,0586,3306,6075,0375,7584,6305,005
Cash flow
Cash from operations2,1176,7813,2282,6892,1043,2932,505
Cash from investing(7,895)(8,363)(1,492)1,1781,137(835)(1,012)
Cash from financing5,8071,995(1,810)(4,400)(868)(2,549)(1,094)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue8,0177,5876,8646,1236,5746,5285,2695,237
Revenue growth (YoY)+22.0%+16.2%+30.3%+16.9%+5.9%---
Other income10613411110915580.6057.5068.50
EBITDA1,9112,1571,7321,9822,0881,9061,3871,461
EBITDA margin+24.5%+29.0%+25.5%+32.8%+32.3%+30.3%+27.1%+28.6%
Depreciation555508360302238238229234
Interest15612313010184.7076.6032.0025.10
Profit before tax1,3071,6601,3531,6871,9211,6721,1841,271
Tax354318388454434423180373
Net profit9521,3419651,2331,4871,2491,004898
EPS (₹)9.3512.6510.3612.5114.5811.6410.179.06
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue11,48615,11810,8188,7337,8357,7806,347
Revenue growth-24.0%+39.8%+23.9%+11.5%+0.7%+22.6%-
EBITDA3,7587,7364,0502,2511,5992,1211,371
EBITDA margin+32.7%+51.2%+37.4%+25.8%+20.4%+27.3%+21.6%
Profit before tax4,3827,4454,2402,0321,1641,6881,617
Net profit3,6915,7323,4351,6211,0961,6331,466
Net profit margin+32.1%+37.9%+31.8%+18.6%+14.0%+21.0%+23.1%
EPS (₹)35.3957.4034.2115.118.3814.4213.80
Balance sheet
Total assets31,40629,79822,10418,63116,09616,84415,088
Net worth23,67221,19015,71613,63913,24012,74411,260
Total debt7,4428,3426,1784,8252,6653,9203,695
Cash & bank734144414248303154385
Net working capital9,6538,7055,9895,2185,1264,5193,527
Cash flow
Cash from operations2,2343,1142,0001,0781,2722,2271,181
Cash from investing570(4,504)(1,832)(1,959)586(2,714)54.60
Cash from financing(2,580)1,384(301)827(1,710)255(967)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,8723,7412,2842,8712,5885,8202,5162,621
Revenue growth (YoY)+11.0%-35.7%-9.2%+9.6%-37.8%---
Other income12449547454215718577.50327
Total expenses2,2851,8592,1451,7192,0032,0471,8671,678
EBITDA5871,8821391,1525853,773648942
EBITDA margin+21.6%+52.8%+6.3%+41.0%+23.5%+67.0%+26.9%+37.5%
Depreciation152151144136130128132134
Interest10311611611413815597.2095.90
Profit before tax4562,1113521,4444753,6754971,039
Tax11638955.9028790.2086126.60250

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 31 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue8,0177,5876,8646,1236,5746,5285,2695,237
Revenue growth (YoY)+22.0%+16.2%+30.3%+16.9%+5.9%---
Other income10613411110915580.6057.5068.50
EBITDA1,9112,1571,7321,9822,0881,9061,3871,461
EBITDA margin+24.5%+29.0%+25.5%+32.8%+32.3%+30.3%+27.1%+28.6%
Depreciation555508360302238238229234
Interest15612313010184.7076.6032.0025.10
Profit before tax1,3071,6601,3531,6871,9211,6721,1841,271
Tax354318388454434423180373
Net profit9521,3419651,2331,4871,2491,004898
EPS (₹)9.3512.6510.3612.5114.5811.6410.179.06
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue51,18045,20219,54717,23715,26515,10214,253
Revenue growth+13.2%+131.2%+13.4%+12.9%+1.1%+6.0%-
Other income5102703111872,58337.20114
Total expenses43,22238,36314,18113,98611,92411,96611,833
Employee cost4,4183,6813,1382,7662,4342,4902,414
EBITDA7,9586,8395,3673,2513,3413,1362,420
EBITDA margin+15.6%+15.1%+27.5%+18.9%+21.9%+20.8%+17.0%
Depreciation1,408916764723713725696
Interest43916681.20130127164342
Profit before tax6,6216,0274,8322,5855,0842,2851,495
Tax1,5951,412978588512147320
Net profit5,4324,6503,8602,3884,3652,3001,437
Net profit margin+10.6%+10.3%+19.8%+13.9%+28.6%+15.2%+10.1%
EPS (₹)50.1044.9938.3619.3743.8220.8411.49
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital101101101101102102102
Reserves & surplus27,01123,85219,72917,41516,89712,89010,273
Shareholders' funds (net worth)27,11123,95319,83017,51617,00012,99210,376
Minority interest2,4712,4052,2722,1722,0541,9371,335
Secured loans2,2072,1500.000.005003842,327
Unsecured loans10,2891,0648041,1953,7214,2005,660
Total debt12,4963,2138041,1954,2214,5847,986
Total liabilities43,60030,82924,27421,21023,65819,87819,979
Assets
Gross block34,31021,70019,92018,34417,71617,34516,782
Net block24,10613,13412,36811,52112,25312,13312,230
Capital work in progress3,6982,6922,4231,201661783742
Investments7,5406,4121,2201,5473,288830765
Inventories5,6283,9443,4423,4133,7193,2362,789
Sundry debtors5,4164,0855,2204,4173,3403,1273,663
Cash & bank balances1,4172,9571,1055731,107888965
Loans & advances1,6701,2051,4009861,5751,2651,086
Total current assets14,13012,19111,1679,3899,7428,5178,503
Total current liabilities7,0725,8604,5614,3523,9843,8873,498
Net working capital7,0586,3306,6075,0375,7584,6305,005
Total assets43,60030,82924,27421,21023,65819,87819,979
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash8274134881,1071,0871,178779
Net cash from operating activities2,1176,7813,2282,6892,1043,2932,505
Net cash from investing activities(7,895)(8,363)(1,492)1,1781,137(835)(1,012)
Net cash from financing activities5,8071,995(1,810)(4,400)(868)(2,549)(1,094)
Net change in cash28.40414(74.80)(534)2,373(90.50)399
Closing cash1,4172,9571,1055731,107888965
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+13.2%+131.2%+13.4%+12.9%+1.1%+6.0%-
EBITDA growth+16.4%+27.4%+65.1%-2.7%+6.5%+29.6%-
PBT growth+9.9%+24.7%+86.9%-49.2%+122.5%+52.8%-37.2%
Net income growth+16.8%+20.5%+61.7%-45.3%+89.8%+60.0%-
Revenue CAGR (3Y)+43.7%+43.6%+9.0%+6.5%+5.1%+8.3%+15.0%
EBITDA CAGR (3Y)+34.8%+27.0%+19.6%+10.3%+4.0%+3.5%+8.4%
Profitability & leverage
Net income margin+9.8%+10.2%+19.7%+11.6%+30.0%+14.2%+8.3%
Return on capital employed+20.3%+24.6%+23.9%+16.3%+14.4%+13.4%+11.7%
Return on net worth+19.7%+21.1%+20.6%+14.1%+29.7%+18.3%+13.8%
Debt / equity0.310.090.050.160.290.540.77
Long-term debt / equity0.080.000.000.010.030.160.35
Interest cover6.702.801.765.144.836.7819.83
Efficiency & per share
Fixed asset turnover1.832.171.020.960.870.890.88
Inventory turnover10.6912.245.704.834.395.015.20
Debtors turnover10.779.724.064.444.724.453.74
EPS (₹)50.1044.9938.3619.3743.8220.8411.49
Dividend per share (₹)1.0011.003.006.002.503.503.50
Book value per share (₹)269.50238.10197.11173.08166.01126.88101.33
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,8723,7412,2842,8712,5885,8202,5162,621
Revenue growth (YoY)+11.0%-35.7%-9.2%+9.6%-37.8%---
Other income12449547454215718577.50327
Total expenses2,2851,8592,1451,7192,0032,0471,8671,678
EBITDA5871,8821391,1525853,773648942
EBITDA margin+21.6%+52.8%+6.3%+41.0%+23.5%+67.0%+26.9%+37.5%
Depreciation152151144136130128132134
Interest10311611611413815597.2095.90
Profit before tax4562,1113521,4444753,6754971,039
Tax11638955.9028790.2086126.60250
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue11,48615,11810,8188,7337,8357,7806,347
Revenue growth-24.0%+39.8%+23.9%+11.5%+0.7%+22.6%-
Other income1,6686961,08554817989.30909
Total expenses7,7287,3826,7686,4826,2365,6594,976
Employee cost1,9661,7621,5081,3221,2051,1471,077
EBITDA3,7587,7364,0502,2511,5992,1211,371
EBITDA margin+32.7%+51.2%+37.4%+25.8%+20.4%+27.3%+21.6%
Depreciation561524504489479451429
Interest48346439127813570.90234
Profit before tax4,3827,4454,2402,0321,1641,6881,617
Tax8221,670798503306212204
Net profit3,6915,7323,4351,6211,0961,6331,466
Net profit margin+32.1%+37.9%+31.8%+18.6%+14.0%+21.0%+23.1%
EPS (₹)35.3957.4034.2115.118.3814.4213.80
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital101101101101102102102
Reserves & surplus23,57121,09015,61613,53813,13812,64211,158
Shareholders' funds (net worth)23,67221,19015,71613,63913,24012,74411,260
Secured loans2,1992,1500.000.00500994357
Unsecured loans5,2436,1936,1784,8252,1652,9263,338
Total debt7,4428,3426,1784,8252,6653,9203,695
Total liabilities31,40629,79822,10418,63116,09616,84415,088
Assets
Gross block10,2948,9008,6778,0007,6767,0096,564
Net block5,0844,2024,3694,1844,3364,1124,109
Capital work in progress6211,188634739384570553
Investments11,47811,4927,2834,8795,1186,4716,404
Inventories2,1781,9521,6871,7821,9261,7801,395
Sundry debtors8,4958,1624,7403,5052,2781,9042,457
Cash & bank balances734144414248303154385
Loans & advances6408201,0701,4212,1102,194556
Total current assets12,04711,0787,9116,9576,6176,0324,793
Total current liabilities2,3942,3731,9221,7381,4901,5131,266
Net working capital9,6538,7055,9895,2185,1264,5193,527
Total assets31,40629,79822,10418,63116,09616,84415,088
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash103108240294154385117
Net cash from operating activities2,2343,1142,0001,0781,2722,2271,181
Net cash from investing activities570(4,504)(1,832)(1,959)586(2,714)54.60
Net cash from financing activities(2,580)1,384(301)827(1,710)255(967)
Net change in cash224(5.10)(132)(54.10)149(231)268
Closing cash734144414248303154385
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-24.0%+39.8%+23.9%+11.5%+0.7%+22.6%-
EBITDA growth-51.4%+91.0%+80.0%+40.8%-24.6%+54.7%-
PBT growth-41.1%+75.6%+108.6%+74.6%-31.1%+4.4%-9.5%
Net income growth-35.6%+66.9%+111.9%+48.0%-32.9%+11.4%-
Revenue CAGR (3Y)+9.6%+24.5%+11.6%+11.2%+9.1%+10.2%+25.3%
EBITDA CAGR (3Y)+18.6%+69.1%+24.1%+18.0%-0.6%+8.8%+62.2%
Profitability & leverage
Net income margin+31.0%+38.2%+31.8%+17.5%+11.0%+19.0%+22.3%
Return on capital employed+15.9%+30.5%+22.7%+13.3%+9.8%+12.2%+13.5%
Return on net worth+15.9%+31.3%+23.5%+11.4%+8.4%+13.6%+14.3%
Debt / equity0.350.390.370.280.250.320.37
Long-term debt / equity0.160.230.320.150.030.090.18
Interest cover15.106.4311.0215.7912.044.2524.82
Efficiency & per share
Fixed asset turnover1.201.721.301.111.071.151.00
Inventory turnover5.568.316.244.714.234.904.43
Debtors turnover1.382.342.623.023.753.572.78
EPS (₹)35.3957.4034.2115.118.3814.4213.80
Dividend per share (₹)1.0011.003.006.002.503.503.50
Book value per share (₹)235.31210.64156.23134.78129.30124.46109.96

To see the full year-wise statements and ratios of Zydus Lifesciences Limited, buy the company report.

Board of directors of Zydus Lifesciences Limited

Zydus Lifesciences has 9 current directors and 10 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Sharvil Pankajbhai Patel
Also directs: Zydus Wellness Limited, Zydus Healthcare Limited, Zandra Infrastructure LLP and 5 more
Managing Director01 Aug 199729 Years 3 MonthsCurrent
Bhadresh Kantilal Shah
Also directs: Welcast Steels Limited, Aia Engineering Limited, Zydus Healthcare Limited and 2 more
Director06 Dec 20187 Years 10 MonthsCurrent
Monappa Arun Akhil
Also directs: Zydus Wellness Limited
Director29 Nov 20223 Years 11 MonthsCurrent
Upasana Konidela
Also directs: Kamineni Enterprises International LLP, Kakatiya Knights LLP, Athamma's Kitchen Private Limited and 5 more
Director29 Nov 20223 Years 11 MonthsCurrent
Mukesh Mangalbhai Patel
Also directs: Solvius LLP, Force Motors Limited, Desai Foods Private Limited and 3 more
Director01 Aug 199729 Years 3 MonthsCurrent
Ganesh Narayan Nayak
Also directs: Zydus Wellness Limited, Zydus Hospira Oncology Private Limited, Zydus Takeda Healthcare Private Limited and 2 more
Director12 Jul 20179 Years 3 MonthsCurrent
Showing 6 of 9 current directors. View all directors

Peer comparison

Zydus Lifesciences Limited is compared with the 9 companies closest to it by revenue in the Pharma industry (Formulations, Lifesciences), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Sun Pharmaceutical Industries Limited₹54,543 Cr (FY 2025)9.0%Vadodara, Gujarat, India
Zydus Lifesciences Limitedthis company₹51,180 Cr (FY 2026)₹5,432.39 Cr10.6%13.2%13,762Ahmedabad, Gujarat, India
Dr.Reddy's Laboratories Ltd₹33,741 Cr (FY 2025)17.0%Hyderabad, Telangana, India
Aurobindo Pharma Ltd₹32,346 Cr (FY 2025)9.0%Hyderabad, Telangana, India
Cipla Limited₹28,409 Cr (FY 2025)7.0%Mumbai, Maharashtra, India
Lupin Limited₹22,904 Cr (FY 2025)14.0%Mumbai, Maharashtra, India
Intas Pharmaceuticals Limited₹21,241 Cr (FY 2025)7.0%Ahmedabad, Gujarat, India
Hetero Labs Limited₹16,537 Cr (FY 2025)13.0%Hyderabad, Telangana, India
Biocon Limited₹16,470 Cr (FY 2025)5.0%Bengaluru, Karnataka, India
Alkem Laboratories Limited₹13,458 Cr (FY 2025)4.0%Mumbai, Maharashtra, India

To see the full peer comparison of Zydus Lifesciences Limited, buy the company report.

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 75.00%, foreign institutional investors hold 6.90%, domestic institutional investors hold 11.30% and retail and other public shareholders hold 6.80%.

Promoters: 75.00%DII (Domestic Institutional): 11.30%FII (Foreign Institutional): 6.90%Retail & Others: 6.80%
Sep 2026
QUARTER
75.00% Promoters
11.30% DII (Domestic Institutional)
6.90% FII (Foreign Institutional)
6.80% Retail & Others
Promoter holding - history
Now 75.00% · Sep 2026High 75.00% · Dec 2025Low 75.00% · Dec 2025
74%74.5%75%75.5%76%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 75.00%Mar 2026: 75.00%Jun 2026: 75.00%Sep 2026: 75.00%75.00%75.00%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters75.00%75.00%75.00%75.00%
Public25.00%25.00%25.00%25.00%

Charges & borrowings

Open charges
₹1,500 Cr
Satisfied charges
₹3,001.83 Cr
Breakdown by lending institutions
Others₹1,500.00 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
21 Dec 201210396390Others₹1,500 CrOpen
24 Dec 201510610473Citi Bank N.A.₹225 CrSatisfied
07 Aug 201410516028Citi Bank N.A.₹93 CrSatisfied
28 May 201410504520Others₹120.4 CrSatisfied
21 Nov 201310465522Citi Bank N.A.₹94.5 CrSatisfied

To see the full charge records of Zydus Lifesciences Limited, buy the company report.

Total charge records: 60 View all charges

Deals & funding

Zydus Lifesciences Limited has 17 deals on record (10 market trades, 5 secondary share transfers, 1 buyback); the latest was in August 2024.

Total deals
17
Market trades
10
Secondary share transfers
5
Buyback
1
Acquisition
1

Deals on record (5 of 17)

WhenDealAmountParties
Mar 2020Acquisition₹2,397.09 CrBuyer: Zydus Animal Health and Investments Limited
Aug 2017Secondary share transferUndisclosedBuyer: Franklin Templeton Asset Management (India) Private Limited , Life Insurance Corporation of India, Government Pension Fund Global, an individual
Seller: Others-Cadila Healthcare Limited
Jul 2010Secondary share transferUndisclosedBuyer: Ramanbhai B Patel Huf, Pankaj R Patel Huf, 2 individuals
Seller: an individual
Jul 2009Secondary share transferUndisclosedBuyer: Zydus Family Trust, Others-Cadila Healthcare Limited
Seller: Zydus Hospitals and Medical Research Pri Vate Limited , 2 individuals
Jul 2008Secondary share transferUndisclosedBuyer: Zydus Hospitals and Medical Research Pri Vate Limited
Seller: Zydus Family Trust

To see the full deal history of Zydus Lifesciences Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Zydus Lifesciences Limited was last rated by Crisil on 08 Oct 2020.

Rating agencyRated onRating
Crisil08 Oct 2020

To see the full credit ratings and regulatory alerts of Zydus Lifesciences Limited, buy the company report.

MSME payment delays

Zydus Lifesciences Limited has 10 MSME Form 1 returns on record between 2019 and 2024, listing 722 overdue payments to 180 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 180)

SupplierAmount dueDue sinceReported on
Ace Technologies & Packaging Systems Private Limited
Vardhamaan Insulaation Limited
CLR Facility Services Private Limited
Sontara Organo Industries
an individual supplier

To see the full MSME payment records of Zydus Lifesciences Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Zydus Lifesciences has 16 subsidiary companies and 3 joint ventures. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.

16
Subsidiary companies
3
Joint ventures
Key subsidiaries
Company NameCINShares held
Zydus Wellness LimitedL15201GJ1994PLC023490
Liva Nutritions LimitedU15149GJ2018PLC105736
Zydus Wellness Products LimitedU15400GJ2019PLC106866
German Remedies Pharmaceuticals Private LimitedU24230GJ2010PTC063425
Zydus Animal Health and Investments LimitedU24236GJ2018PLC102269
Zydus Pharmaceuticals LimitedU24290GJ2019PLC111689

To see the full group structure of Zydus Lifesciences Limited, buy the company report.

Employees & EPFO

Zydus Lifesciences Limited has a workforce of 13,762 employees on its EPFO records as of Jan 16, 2025, across 8 active EPFO establishments.

Employee count
13,762
Active EPFO establishments
8
Employee growth
5.09%

GST

Zydus Lifesciences has 38 GST registrations: 27 active and 11 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
38
Active
27
Cancelled / inactive
11
GSTINStateStatusRegistered on
24AAACC6253G1ZZGujaratActive01 Jul 2017
24AAACC6253G2ZYGujaratActive06 Jul 2017
24AAACC6253G3ZXGujaratActive22 Jul 2017
02AAACC6253G1Z5Himachal PradeshActive01 Jul 2017

To see the full GST registrations and return filing status of Zydus Lifesciences Limited, buy the company report.

Recent activity

Zydus Lifesciences Limited has 27 board changes on record since 1995: 19 appointments and 8 cessations. The latest: Kulin Sanjay Lalbhai was appointed as Director on 19 May 2026.

AGM
Zydus Lifesciences Limited last Annual general meeting of members was held on 11 Aug 2026 as per latest MCA records.
Appointed
Kulin Sanjay Lalbhai was appointed as Director.
Filing
Zydus Lifesciences Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
Appointed
Tushar Dhansukh Shroff was appointed as CFO.
Ceased
Nitinkumar Dalsukhray Parekh ceased to be CFO.
Ceased
Dharmishta Narendraprasad Raval ceased to be Director.
Ceased
Nitin Raojibhai Desai ceased to be Director.
Appointed
Shelina Pranav Parikh was appointed as Director.
Appointed
Monappa Arun Akhil was appointed as Director.
Appointed
Upasana Konidela was appointed as Director.
Charges
A charge with Others of Rs. 1,500.00 Cr registered on 21 Dec 2012 with Charge ID 10396390 was modified on 20 Apr 2022.
Charges
A charge registered on 28 May 2014 via Charge ID 10504520 with Others was fully satisfied on 09 Dec 2020.

150 earlier events are in the company report.

News

US FDA Flags Issues In Co's Data Integrity; US FDA Had Issued 5 Observations At Moraiya Unit ( Zydus Life ) - TV
26 Oct 2026 · Exchange Update
Zydus Lifesciences: Gets Final USFDA Approval For Estradiol And Levonorgestrel Transdermal System; Eligible For 180-Day CGT Exclusivity; Expected Annual Sales Around USD 45.7 Million In The US
21 Oct 2026 · Exchange Update
Zydus Lifesciences: Subsidiary Zylidac Bio Teams Up With Prolific Machines To Enhance Optogenetics-Based Biologics Production To GMP Standards.
21 Oct 2026 · Exchange Update
Zydus Lifesciences: Company Signs Deal With Sri Lanka's Board Of Investment To Build A Pharmaceutical Plant; Project Will Cost Over $20 Million; Operations To Begin In 2028.
15 Oct 2026 · Exchange Update
Zydus Lifesciences: Bernstein on Zydus Lifesciences Maintains Buy, Target Price ₹1,457; US FDA acceptance for review of FYB206, a Keytruda biosimilar, reinforces Zydus’ strategy of building a biologics and novel-drug franchise for the US; Bernstein sees it as the first and currently only pembrolizumab biosimilar accepted for review, with potential FDA action in Q3 2027, estimates a US$7–8bn contestable year-one post-patent-loss IV market and projects US$500mn in base-case gross end-market sales for Zydus, translating to around US$150mn annual gross profit before commercial expenses under its licensing assumptions.
14 Oct 2026 · Exchange Update
Zydus Lifesciences: Company's FYB206 is the First Keytruda Biosimilar Accepted for USFDA Review.
13 Oct 2026 · Exchange Update

From our blog

Frequently asked questions

Zydus Lifesciences is an active public limited company based in Ahmedabad, Gujarat, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 15 May 1995 (31+ years old) and is registered under CIN L24230GJ1995PLC025878. Listed on BSE: 532321 and NSE: ZYDUSLIFE.

Zydus Lifesciences reported revenue of ₹51,180 Cr for FY 2025-26 (up 13.2% YoY) based on consolidated financials.

Zydus Lifesciences has 9 current directors:

The latest financial statements of Zydus Lifesciences on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 11 August 2026. Year-wise statements from 2015 are in the company report.

The GSTIN of Zydus Lifesciences is 24AAACC6253G1ZZ, registered in Gujarat. The company has 38 GST registrations in all, of which 27 are active and 11 are cancelled or inactive. Other active GSTINs include 24AAACC6253G2ZY (Gujarat), 24AAACC6253G3ZX (Gujarat), 02AAACC6253G1Z5 (Himachal Pradesh).

The CIN (Corporate Identification Number) of Zydus Lifesciences is L24230GJ1995PLC025878. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Zydus Lifesciences is a listed company as per MCA records. Its shares are listed on both BSE (code: 532321) and NSE (symbol: ZYDUSLIFE).

Zydus Lifesciences has 167 court cases on record: 128 filed by the company and 39 filed against it. 63 are pending. Most are in the district courts.

Zydus Lifesciences was incorporated on 15 May 1995, making it 31+ years old. It is registered with the Registrar of Companies, Ahmedabad.

Zydus Lifesciences has 17 deals on record (10 market trades, 5 secondary share transfers, 1 buyback); the latest was in August 2024.

The peers of Zydus Lifesciences by revenue are Sun Pharmaceutical Industries Limited, Dr.Reddy's Laboratories Ltd, Aurobindo Pharma Ltd, Cipla Limited, Lupin Limited and 4 more, all in the Pharma industry (Formulations, Lifesciences), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

Kulin Sanjay Lalbhai was appointed as Director on 19 May 2026. Tushar Dhansukh Shroff was appointed as CFO on 16 Sep 2025. Nitinkumar Dalsukhray Parekh ceased to be CFO on 31 Aug 2025. Zydus Lifesciences has 27 board changes on record in total.